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Here we report the unexpected finding that specific human ANK2 variants represent a new example of balanced human
variants. The prevalence of certain ANK2 (encodes ankyrin-B) variants range from 2 percent of European individuals to 8
percent in individuals from West Africa. Ankyrin-B variants associated with severe human arrhythmia phenotypes (eg E1425G,
V1516D, R1788W) were rare in the general population. Variants associated with less severe clinical and in vitro phenotypes
were unexpectedly common. Studies with the ankyrin-B
+/2 mouse reveal both benefits of enhanced cardiac contractility, as
well as costs in earlier senescence and reduced lifespan. Together these findings suggest a constellation of traits that we term
‘‘ankyrin-B syndrome’’, which may contribute to both aging-related disorders and enhanced cardiac function.
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INTRODUCTION
Ankyrins -R, -B, and -G are a versatile family of membrane-
associated adaptors that were first discovered based on the role of
ankyrin-R in mediating membrane attachment of spectrin in
human erythrocytes [1–3]. Consistent with this function, muta-
tions in ankyrin-R are the major cause of hereditary spherocytosis,
a disorder associated with spectrin deficiency and increased
membrane fragility in humans [4–6]. Ankyrins-G and -B are
expressed in non-erythroid tissues, where they function in the
maintenance and establishment of specialized membrane domains
by interacting with a diverse set of membrane proteins. Ankyrin-G
is required for accumulation of voltage-gated sodium channels in
excitable membranes at axon initial segments of neurons [7,8] and
at transverse-tubules in cardiomyocytes [9]. A cardiac voltage-
gated sodium channel SCN5A human variant that abolishes
binding of Nav1.5 with to ankyrin-G results in Brugada syndrome,
which is a dominantly-inherited fatal cardiac arrhythmia [9].
Ankyrin-G also is required for biogenesis of the lateral membrane
of epithelial cells and pre-implantation embryos [10,11]. Loss of
ankyrin-G function thus would likely have major consequences
beginning in early development. In contrast to ankyrin-G,
ankyrin-B has more specialized roles, and is required for postnatal
life in mice but not for prenatal survival [12].
Loss-of-function variants in ANK2 (encodes ankyrin-B) cause
a dominantly-inherited cardiac arrhythmia with increased risk for
sudden cardiac death, initially termed type 4 long QT syndrome,
and more recently renamed sick sinus syndrome with bradycardia
or the ‘‘ankyrin-B syndrome’’ ([13–15]; OMIM). Mice heterozy-
gous for a null mutation in ankyrin-B have a similar arrhythmia to
humans and exhibit sudden death following administration of
catecholamines and/or exercise [14]. Studies with ankyrin-B
+/2
cardiomyocytes revealed that the basis for sudden death associated
with the arrhythmia is elevation of calcium transients in the
context of sympathetic stimulation [14]. The cellular basis for
altered calcium dynamics in ankyrin-B
+/2 cardiomyocytes has
been proposed to result from a deficiency of a complex of ankyrin-
B with the Na/K ATPase, Na/Ca exchanger, and IP3 receptor
localized in a specialized microdomain in cardiomyocyte
transverse-tubules [16]. Loss of additional signaling molecules
from ankyrin-B
+/2 myocytes may also influence the cellular
phenotype in ankyrin-B deficiency [17].
Abnormal calcium dynamics in ankyrin-B
+/2 neonatal cardio-
myocytes can be rescued by expression of wild-type human
ankyrin-B but not by ankyrin-B with variants associated with
cardiac arrhythmia [13,14,18]. These ankyrin-B variants demon-
strate clear functional differences in vitro. However, similar to other
inherited arrhythmia syndromes [19,20], the penetrance of the
sudden cardiac death phenotype in families with ankyrin-B
variants can be relatively low. For example, in the first family
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displayed sinus node dysfunction, atrial fibrillation, and ventricular
arrhythmia, only 2 of the 21 heterozygotes experienced fatal
outcomes [14]. Moreover, specific ankyrin-B variants associated
with minor cellular phenotypes may be relatively common in
specific human populations [21].
Here, we present evidence that specific ankyrin-B variants
represent a new example of balanced variants in humans. The
prevalence of ankyrin-B variants varied from 2 percent of
European to 8 percent in individuals from West Africa. Moreover,
African and European populations also exhibit distinct patterns of
ankyrin-B variants. Studies with the ankyrin-B
+/2 mouse reveal
both benefits of enhanced cardiac contractility, as well as costs in
earlier senescence and reduced lifespan. Together these findings
suggest a constellation of traits that we term ‘‘ankyrin-B
syndrome’’, which may contribute to both aging-related disorders
and enhanced cardiac function.
MATERIALS AND METHODS
Protein Alignment
Protein alignments were performed in CLUSTALW using the
following protein sequences from NCBI: Homo sapiens
gi|119626696|gb|EAX06291.1; Macaca mulatta gi|109075425|
ref|XP_001095471.1; Canis familiaris gi|74002173|ref|XP_
545031.2; Mus musculus gi|37590265|gb|AAH59251.1|; Rattus
norvegicus gi|109467596|ref|XP_001076082.1|; Pan troglodytes
gi|114595754|ref|XP_517403.2; Gallus gallus gi|118090374|
ref|XP_420641.2.
Genetic Studies
ANK2 variants reported previously to have functional conse-
quences in cardiomyocytes were used for genotyping genomic
DNA samples from West Africans residing in the country of
Ghana (collected by Rand Allingham and co-workers, Duke
University Dept. of Ophthalmology) and Europeans (collected by
the Associazone Longevita, Italy). SNP genotyping was deter-
mined using the ABI 7900HT Taqman SNP genotyping system
(Applied Biosystems, Foster City, California, United States), which
uses a PCR-based allelic discrimination assay in a 384-well–plate
format with a dual laser scanner. Allelic discrimination assays were
purchased from Applied Biosystems, or, if the assays were not
available, primer and probe sets were designed and purchased
through Integrated DNA Technologies (Coralville, IA,). Successful
genotyping was obtained for greater than 95% of the DNA
samples used in the study.
Animal care
Ankyrin-B
+/2 mice [12] were backcrossed .10 generations
(.99.5% pure) into a C57/Bl6 background before experiments.
Both ankyrin-B
+/2 and wild-type littermates mice were housed in
the same facility (temperature and humidity), consumed the same
diet (Lab Diet, 23% protein, 4.5% fat, 6.0% fiber, 8.0% ash, 2.5%
minerals (0.95% Ca2+, 0.67% phosphorus, 0.40% non-phytate
phosphorus), 56% complex carbohydrate from overhead wire
feeders) and water ad libitum, and were kept on identical 12 hour
light/dark cycle. Food intake was monitored over 24 hour periods
and averaged over 2–3 days in mice individually housed.
3H ouabain-binding
Equilibrium [
3H] ouabain binding was performed on isolated live
adult cardiomyocytes (.70% rod-shaped) for 60 min at 35uCi n
modified Tyrode’s buffer (0.5 mM KCl). Non-specific binding was
determined as binding in the presence of 10 mM non-radioactive
ouabain. Membranes were separated from buffer and sequentially
washed by vacuum filtration in cold buffer followed by liquid
scintillation counting.
Mouse echocardiograms
Two-dimensional guided M-mode echocardiography was per-
formed using an HDI 5000 echocardiograph (ATL, Bothell, WA)
as previously described [22–25]. Mice were studied in a conscious
state using gentle manual restraint after a period of acclimation
[23]. A soft plastic collar was fashioned to prevent the animals
from biting the probe. Mice were studied in a conscious state. For
pressure overload induced cardiac failure, mice were anesthetized,
intubated; the chest was opened in the second intercostal space. A
7-0 suture was placed around the transverse aorta and tied to a 27
gauge needle to create aortic constriction [23,26]. The needle was
then recovered, mice were allowed to recover, and follow-up
echocardiograms were performed on wild-type and ankyrin-B
+/2
mice seven days post-ligation as described [23,26]. Fractional
shortening values were compared between wild-type and ankyrin-
B
+/2 mice over a range of similar pressure gradients. Values
represent mean6standard error.
Mouse studies
Animal care was in accordance with institutional guidelines. Wild-
type (n=6) and ankyrin-B
+/2 mice (n=6) were implanted with
radiotelemetry transmitters [14]. Following an intraperitoneal
injection of a low (100 mg/kg) or high dose (10 mg/kg) of ouabain,
or 2 mg/kg epinephrine conscious mice were monitored for heart
rate, syncope, or death.
Preparation of Adult Cardiac Myocytes and
Contractility Studies
Mice used in these studies were female adult WT C57BL/6 mice
and ankyrin-B
+/2 littermates (C57 BL/6), or wild-type and
PLN
2/2 littermates (129), 3–6 months of age and weighing 30–
40 g. Animals were handled according to approved protocols and
animal welfare regulations of the Institutional Review Board
(DUMC). Mouse ventricular cardiomyocytes were isolated as
described in [27]. Myocytes were isolated and visualized with an
inverted microscope (Nikon Eclipse TE 300). Single-cell contrac-
tion was measured by video edge detection, and recordings were
made under basal conditions and after administration of 100 mM
ouabain [27]. Cellular shortening was measured for 15–20 cells of
equal length/mouse to determine the mean cellular shortening per
mouse under each condition. Values reported represent mean6-
standard deviation of cellular shortening for 4–5 mice.
Temperature measurements
Following anesthesia, six month mice were surgically implanted
with radiotelemetry temperature probes (Data Sciences Interna-
tional). Five days after surgery, the temperature of non-
anesthetized animals was determined.
Immunofluorescence and Immunoblotting
Freshly extracted pancreas from wild-type C57B/6 and ankyrin-
B
+/2 C57B/6 mice was fixed for 18 hours at 4uCi n4 %
paraformaldehyde. Tissues were embedded and sectioned at
10 mm thickness. Primary antibody incubation was performed
for 18 hours at 4uC and slides were washed thoroughly with
a solution of phosphate buffered saline, pH 7.4 (PBS) +0.1%
Triton X-100 (v/v). Incubation with secondary antibodies was
Human Ankyrin-B Gene Variants
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PBS +0.1% (v/v) Triton X-100. Pancreas sections were analyzed
using the following antibodies: insulin (Santa Cruz, Chemicon)
glucagon (Sigma), somatostatin (Chemicon), and ankyrin-B.
Antibodies
Primary antibodies included rabbit anti-insulin (Santa Cruz
Biotechnology); rabbit anti-somatostatin (Chemicon Internation-
al); mouse anti-glucagon (Sigma); affinity-purified ankyrin-B
monoclonal and polyclonal Ig. Secondary antibodies included
goat anti-rabbit and goat anti-mouse Alexa Fluor 488 and 568
(Molecular Probes).
Survival Curve
Ankyrin-B
+/2 mice (n=100) and their wild-type littermates
(n=100) (C57B/6) were monitored for three years. Each group
of mice were kept in identical environments. Relative survival for
each genotype was calculated as a per cent cumulative survival of
its group (either wild-type or ankyrin-B
+/2). Evaluation continued
until all mice within each population died (0% survival).
Immunoblotting
Immunoblots were performed as previously described[12]. Prima-
ry antibody incubation was performed for 18 hours at 4uC with
gentle rocking. Blots were rinsed using three 15-minute washes in
16TTBS. Immunoblotting was performed as described [12] using
125I-labelled Protein A. Signals were quantitated by phosphorima-
ging.
Statistics
Data were analyzed using either paired two-tailed t tests or two-
way ANOVA, and P values less than 0.05 were considered
significant (*).
RESULTS
Prevalence of ankyrin-B variants in human
populations
An initial screen for ankyrin-B variants in arrhythmia patients
detected individuals with several mis-sense variants in the ankyrin-
B gene [14,15]. These variants include E1425G, L1622I, T1626N,
R1788W, and E1813K [14,15]. Comparison of ankyrin-B protein
primary sequence from different species (Figure 1B) shows that the
identified variants are highly conserved in vertebrates. Of the six
variants shown, only T1626N does not show 100% sequence
identity from humans to chickens. The high degree of conserva-
tion across species suggests that these residues are likely to be
critical for ankyrin-B stability and/or function. It was therefore
unexpected when Sherman and colleagues reported that certain
ankyrin-B gene variants were present in healthy Caucasian and
African American individuals [21]. Notably, L1622I was found in
4% of African-Americans in this study. One intriguing possibility is
that the apparent discrepancy is due to ethnic differences in
ankyrin-B SNP allele frequency.
Thus, we first determined the allele frequencies of these genetic
variants in defined ethnic populations. We decided to explore the
differences between white and black populations. In order to do
this, we obtained genomic DNA samples from European and
African populations. Since African-Americans represent an
admixture of Caucasian, African, and Native American haplotypes
that would confound our analysis, we chose to exclude them from
this initial study.
We genotyped 384 west African and 1152 European individuals
using a PCR-based allelic discrimination assay. Figure 1c shows
the allele frequency of each variant in the European (black) and
west African (red) populations tested, as well as the allele frequency
of the pooled functional variants (Total). L1622I was surprisingly
common in Africans, and was present in ,8.6% of the individuals
genotyped. It was the only variant detected in the west African
population. In the European population, all SNPs had an allele
frequency of less than 0.01, though combined, 2.1% of the
European sample had a loss of function ankyrin B variant.
As discussed later, ankyrin-B
+/2 mice demonstrate signs of
accelerated senescence compared to litter matched controls (see
below). Using population tools, we next evaluated whether there
were negative consequences for longevity in individuals with
ankyrin-B variants. If so, we would predict these variants to be
depleted or absent in centenarians (humans that reach the age of
100). The European genomic DNA samples used in the population
study were a collection of 768 centenarians and 384 non-
centenarians obtained from the Associazone Longevita in Italy.
Figure 1D shows the allele frequency of the each variant in non-
centenarians (black) and centenarians (red). Centenarians had
a reduced frequency of variants at 1.6 percent compared to non-
centenarians with 2.4 percent. However, the association between
ankyrin-B variants and centenarian status was not significant (for
combined ankyrin-B loss-of-function variants p=0.3570 for
Fischer’s exact test, p=0.3501 for chi-squared test). However, we
believe that the high p value is likely to result from a lack of power at
this sample size. Given the low allele frequency of these variants, the
p value could be improved by increasing the numbers of individuals
tested in each group. At the proportions seen in this study, we would
need approximately 6000 patients to get a significant p value. We
hope to address this study limitation in the future.
These data indicate that specific ankyrin-B gene variants are
both more common than expected and segregated with respect to
ethnicity. Negative consequences for those having a function
ankyrin-B variant may include both susceptibility to cardiac
arrhythmia and reduced longevity. However, the prevalence of
these variants and racial differences detected in their frequency
suggest the interesting possibility that these ankyrin-B variants may
benefit organism survival.
Increased contractility of ankyrin-B
+/2
cardiomyocytes
We next explored whether ankyrin-B haploinsufficiency could
provide a benefit to the mouse. Ankyrin-B
+/2 cardiomyocytes
exhibit a 16 percent elevation in calcium transients [14], which has
been proposed to result from loss of Na/K ATPase localized in
a complex with ankyrin-B as well as the Na/Ca exchanger and
InsP3 receptor [16]. Elevated intracellular calcium transients in
ventricular cardiomyocytes would lead to enhanced contractility,
which would increase cardiac output. These findings suggested the
hypothesis that ankyrin-B deficiency mimics effects of cardiac
glycosides, which inhibit the Na/K ATPase, cause elevation in
intracellular calcium stores, and increase cardiac contractility as
a positive outcome.
We first compared effects of ouabain and ankyrin-B-deficiency
on cellular shortening in freshly isolated unloaded wild-type and
ankyrin-B
+/2 adult ventricular cardiomyocytes. The extent of cell
shortening provides a functional readout of [Ca
2+]i transients and
contractility, since cardiomyocytes respond to elevated calcium
levels by contraction. Field-stimulated wild-type cardiomyocytes
exhibited 12.3% shortening (n=5 mice) that increased ,1.7-fold
to 20% in the presence of 100 mM ouabain (a saturating
Human Ankyrin-B Gene Variants
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1051concentration) (Figure 2A, p,0.01). In contrast, ankyrin-B
+/2
cardiomyocytes exhibited 15% basal shortening (n=4 mice),
a value significantly greater than that of unloaded wild-type
cardiomyocytes (p,0.01). Ankyrin-B
+/2 cardiomyocytes were
further activated by 100 mM ouabain to 20% shortening, or
a ,1.3-fold increase (Figure 2A, p,0.01). Untreated ankyrin-B
+/2
cardiomyocytes thus behave as if they were treated with ouabain,
with increased basal levels of contraction. In response to treatment
with maximal concentrations of ouabain, wild-type and ankyrin-
B
+/2 cardiomyocytes are activated to the same final extent. These
results suggested that the fraction of Na/K ATPase missing in
ankyrin-B
+/2 cardiomyocytes accounts for ,38% of the maximal
contractile response to ouabain.
There is considerable uncertainty regarding which isoforms of
the Na/K ATPase are physiological targets for cardiac glycosides
and in which species [28,29]. Therefore we determined effects of
ankyrin-B deficiency in mouse cardiomyocytes on the affinity and
capacity for
3[H]-ouabain, which is a commonly used cardiac
glycoside (Figure 2B–C). Freshly isolated cardiomyocytes from
ankyrin-B
+/2 mice have reduced numbers (,15%) of surface
3H-ouabain-binding sites, but similar affinity for ouabain com-
pared to cells derived from wild-type littermates (wild-type
Bmax =1.90 pmol/mg (Kd=31.3 nM); ankyrin-B
+/2 Bmax=
1.61 pmol/mg (Kd=33.1 nM); Figure 2C). Scatchard plots reveal
a single class of ouabain-binding sites for both wild-type and
ankyrin-B
+/2 cells, suggesting that the sites lost in ankyrin-B
+/2
Figure 1. Human ankyrin-B gene variants have unique distributions in distinct ethnic populations and may affect longevity. A. The domain
structure of 220 kD ankyrin-B protein, showing the N-terminal membrane binding domain (red), spectrin-binding domain (green), death domain
(yellow), and C-terminal domain (blue). Magnified insert shows the location of previously identified variants. Variants had range of functional severity
in mouse cardiomyocytes, indicated with yellow (mild), gray (moderate) or red (severe) bars. B. Affected residues are highly conserved across species.
Ankyrin-B alignment from human, monkey, rat, mouse, dog, chicken, and zebrafish. Residues affected by the nucleotide variants are shown in red. C.
Allele frequency of the ANK2 variants in 1152 Europeans (black bars) and 384 West Africans (red bars) as determined by PCR based allelic
discrimination assay. Right, Allele frequency of pooled functional variants. D. Ankyrin-B variants are less frequent in Europeans that reach the age of
100. Allele frequency of the each variant in European non-centenarians (black bars) and centenarians (red bars). Asterisks indicate that no individuals
were identified with the variant.
doi:10.1371/journal.pone.0001051.g001
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These data with isolated cardiomyocytes are consistent with
a ,15% reduction in level of both Na/K ATPase a1 and a2
isoforms in ankyrin-B
+/2 heart tissue determined previously [14].
Na/K ATPase expression and localization at sarcolemmal and
intercalated disc membranes is unaffected in ankyrin-B
+/2 cells
[14]. Therefore, loss of T-tubule-associated Na/K ATPase is
paralleled by loss of a small population of ouabain-binding sites
(,16%) in ankyrin-B
+/2 cardiomyocytes that have the same
affinity for ouabain as the residual binding sites.
Enhanced cardiac function in ankyrin-B
+/2 mice
The finding that loss of ankyrin-B-coupled Na/K ATPase mimics
effects of cardiac glycosides in isolated ankyrin-B
+/2 cardiomyo-
cytes, suggested the hypothesis that ankyrin-B
+/2 mice also have
enhanced cardiac function. Digitalis has a relatively subtle effect
on the unstressed heart with a normal left ventricular (LV)
pressure, and at one point was believed to only act in the context
of heart failure [30]. We therefore measured left ventricular (LV)
fractional shortening (an intact heart correlate of cellular
shortening and one measure of cardiac function) by echocardiog-
raphy in conscious mice before and after induction of LV pressure
overload. LV pressure overload was induced by transverse aortic
constriction (TAC; [22]). Before TAC, ankyrin-B
+/2 mice
displayed a modest, but significant 10% increase in percent
fractional shortening compared to wild-type mice (wild-
type=58.361.9%, n=16; ankyrin-B
+/2=63.961.5% n=15
mice; p,0.05; Figure 2D). Following TAC for seven days that
induced similar increases in LV pressure overload as measured by
the trans-stenotic gradient (see Figure 2E), ankyrin-B
+/2 mice
exhibited preservation of higher fractional shortening
Figure 2. Loss of ankyrin-B-dependent [
3H]-ouabain-binding sites mimics the cellular action of digitalis. (A) Isolated unloaded ankyrin-B
+/2
ventricular cardiomyocytes display increased cellular shortening compared to unloaded WT cardiomyocytes, consistent with increased [Ca
2+]i
transients [14]. Asterisk represents p,0.01 between untreated WT and ankyrin-B
+/2 cardiomyocytes (15–20 cardiomyocytes from 4–5 mice). WT and
ankyrin-B
+/2 cardiomyocytes treated with maximal doses of ouabain (100 mM) display significant elevations in cellular shortening compared with
untreated WT and ankyrin-B
+/2 cardiomyocytes (15–20 cardiomyocytes from 4–5 mice, p,0.01, asterisks). (B–C) Live, isolated ankyrin-B
+/2
cardiomyocytes display reduced (,20%) surface expression as measured by binding of [
3H]-ouabain (n=3, p,0.01). (D–E) Conscious
echocardiograms of wild-type and ankyrin-B
+/2 mice before and after transverse aortic constriction. Black labels represent wild-type animals,
white labels represent ankyrin-B
+/2 data. Ankyrin-B
+/2 mice show preserved fractional shortening compared to wild-type mice over a wide range of
hemodynamic stress (induced through transverse aortic constriction).
doi:10.1371/journal.pone.0001051.g002
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,74% decline in fractional shortening to 29.867.9%, n=9;
p,0.05 observed in wild-type animals. Therefore, one benefit of
loss of ankyrin-B-coupled Na/K ATPase is preservation of cardiac
function under conditions of elevated afterload induced by
hemodynamic stress.
Ankyrin-B
+/2 mice display reduced sensitivity to
ouabain-induced arrhythmia
Enthusiasm for clinical use of cardiac glycosides has subsided due
to their capacity to promote fatal cardiac arrhythmias. The results
with isolated adult cardiomyocytes suggested the possibility that
ankyrin-B
+/2 mice might be at least partially resistant to
proarrhythmic effects of ouabain. We evaluated effects of ouabain
on heart rate and rhythm by measuring electrocardiograms in
conscious animals using implanted wireless transmitters (Figure 3).
Intraperitoneal injection of a low, sub-lethal dose of ouabain
(100 mg/kg) leads to an expected modest decrease in heart rate in
6/6 wild-type mice tested, but no effect in ankyrin-B
+/2 mice,
which already have bradycardia [14]. Lethal doses of ouabain
(10 mg/kg) caused polymorphic arrhythmia in wild-type C57BL/
6 WT mice (Figure 3A; 8/8 mice) within 16 minutes of injection,
followed by death (6/8). Identical injections of lethal doses of
ouabain to C57BL/6 ankyrin-B
+/2 littermate mice did result in
decreased heart rate (8/8), but no significant ventricular
arrhythmias (1/8), and, remarkably, no death (0/8; Figure 3C).
Ankyrin-B
+/2 mice thus are resistant to ouabain in three
functional readouts: reduction in heart rate, ventricular arrhyth-
mia, and death [31].
Figure 3. Ankyrin-B
+/2 mice are resistant to ouabain-induced ventricular arrhythmia and death. Wild-type (n=8) and ankyrin-B
+/2 mice (n=8),
and wild-type (n=10) and phospholamban-null mice (n=10) were surgically-implanted with radiotelemetry ECG probes. Mice were injected with
a high dose (10 mg/kg) of ouabain or 2 mg/kg epinephrine, and conscious ECGs were recorded. Unlike wild-type or phospholamban-null mice,
ankyrin-B
+/2 mice display resistance to ouabain-induced ventricular arrhythmia (1/8) and death (0/8). Panel A represents ECG data from wild-type,
ankyrin-B
+/2, and PLN null mice treated with ouabain. Data in panels B–D represent summary syncope, death, and arrhythmia data for mice following
exercise (panel B), exercise plus epinephrine injection (panel C), and ouabain injection (panel D).
doi:10.1371/journal.pone.0001051.g003
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+/2 mice are not intrinsically resistant to all forms of
arrhythmia since strenuous exercise plus injection of high doses of
epinephrine caused ventricular arrhythmia, syncope, and death in
,75% of ankyrin-B
+/2 mice[14]. However,a trivialexplanationfor
ouabain-resistance of ankyrin-B
+/2 mice could be that chronic
elevation of [Ca
2+]i transients in ankyrin-B
+/2 cardiomyocytes
caused compensatory adaptations. Phospholamban-null mice
have chronic elevation of [Ca
2+]i transients comparable to
ankyrin-B
+/2 mice due to increased Ca-affinity of SERCA2 [32]
and provide a control for generalized Ca
2+-induced changes in
protein expression. Phospholamban-null mice in a 129 background
respond to high doses of ouabain with a similar arrhythmia (9/10)
and death (8/10) in the same manner as C57BL/6 WT mice (8/8,
6/8) and 129 WT mice (9/10,8/10; Figure 3C). Ankyrin-B
+/2 mice
thus are resistant to ouabain-induced cardiac arrhythmia due to
a mechanism independent of adaptation to chronic Ca
2+ elevation.
Ankyrin-B
+/2 mice display premature senescence
and reduced longevity
As ankyrin-B mutant mice aged we noticed a consistent pattern of
kyphosis, hair loss and general deterioration compared to their
littermates. We therefore evaluated senescence in ankyrin-B
+/2
mice. Consistent with premature aging, we observed decreased
soft tissue mass in .12 month ankyrin-B
+/2 animals (see 12 and
24 month animals in Figure 4A–C). In fact, when compared to
their age-matched wild type littermates, ankyrin-B
+/2 mice
demonstrate a loss of adiposity that begins at 6 months of age
and progresses until death (Figure 4). This loss is not due to
a decrease in food intake or core body temperature. These mice
consume similar quantities of rodent chow, and have similar
conscious body temperatures (not shown). Moreover, ankyrin-B
+/
2 mice display severe kyphosis which begins at 6 months of age
and becomes increasingly pronounced in two year ankyrin-B
+/2
mice, Figure 4A–C, bottom panels). Ankyrin-B
+/2 mice (.1 yr) also
have an impaired ability to re-grow hair (Figure 4D). Hair growth
requires functioning stem cells, suggesting these animals may have
impaired stem cell regeneration, which can promote premature
senescence (Figure 4F) [33]. Histological evaluation of the dorsal
skin sections of two-year old wild-type and ankyrin-B
+/2 mice show
a decrease in sub-dermal adipose tissue when compared with wild-
typelittermates,whichalsoisaphenotypeconsistentwithsenescence
(Figure 4E). Finally, the life-span of ankyrin-B
+/2 mice is
significantly reduced compared with wild-type littermate controls
(Figure 4F). Specifically, ankyrin-B
+/2 mice live on average to ,90
weeks; while their wild-type littermates survive to ,120 weeks
(consistent with the C57Bl6 life-span [34]). These data demonstrate
that accelerated aging is a highly penetrant consequence of ankyrin-
B-deficiency in mice. A future goal will be to further explore the link
between these longevity data in mice with preliminary human
ankyrin-B variant data presented in Figure 1D.
Ankyrin-B-haploinsufficiency in multiple cell types
As a first step in determining possible physiological differences
underlie the complex phenotype of ankyrin-B
+/2 mice, we
evaluated in these mice the pattern of expression of ankyrin-B.
220 kD ankyrin-B is abundantly expressed in both brain, heart
and thymus [12,35]. Ankyrin-B also is present at detectable levels
in skeletal muscle, kidney, lung, testes, spleen and lung, and is
reduced about 50 percent in all of these tissues in ankyrin-B
+/2
mice (Figure 5A–B).
We next determined the cell types expressing ankyrin-B in
several tissues. In the pancreas, ankyrin-B is highly expressed in
isletsandisvirtuallyabsentfromsurroundingacinarcells(Figure5C).
Within pancreatic islets, ankyrin-B staining was concentrated in beta
cells and virtually absent from alpha cells (glucagon-positive) or delta
cells (somatostatin-positive) (Figure 5D–E). Ankyrin-B immunostain-
ing in b-cells is significantly reduced in ankyrin-B
+/2 pancreas
(Figure 5B, 5F–G). Identical labeling and imaging protocols (see
Methods) revealed an approximate 47% decrease in the intensity ratio
of ankyrin-B/glucagon in ankyrin-B
+/2 islets compared to wild-type
islets (+/+, 0.9060.1; +/2,0 . 4 8 60.1, n=20, p,0.05). As ankyrin-
B expression in acinar cells is minimal, the reduction of ankyrin-B by
quantitative immunoblot in pancreas (Figure 5B) is due primarily to
loss of ankyrin-B in beta cells.
In the heart, reduced expression o fa n k y r i nBp r o t e i nr e s u l t si n
decreased levels of ankyrin-binding partners IP3 receptor, Na/Ca
exchanger and Na/K ATPase. The loss of these channels/
transporters in critical microdomains of cardiomyocyte transverse-
tubules/sarcoplasmic reticulum is believed to be the basis of the
arrhythmia phenotype. [16]. We determined that ankyrin-B
haploinsufficiency also results in loss of IP3 receptor in other cell
types, including Purkinje neurons in the cerebellum and bronchial
epithelial cells in the lung as a correlate of ankyrin-B function in these
cells (Figures S1,S2,S3).Future workwill investigate the consequences
of ankyrin-B deficiency at a molecular level, and determine which cell
types contribute to the global phenotype of the ankyrin-B mouse.
DISCUSSION
This study reports that certain loss-of-function variants in the
ANK2 gene are present in ‘‘normal’’ European and west African
populations. The frequency of these variants is surprising given the
high degree of protein conservation between species and within
most human populations. Mice heterozygous for a null mutation
in ankyrin-B have previously been demonstrated to have a similar
cardiac arrhythmia as humans with ankyrin-B variants [14,15].
Further characterization of ankyrin-B
+/2 mice in this paper reveal
a heretofore unrecognized syndrome of increased cardiac
contractility and resistance to cardiac glycoside-induced arrhyth-
mia that is balanced by premature senescence. Ankyrin-B is co-
expressed with IP3 receptors in specific cell types including
Purkinje neurons and bronchial epithelial cells. Interestingly, both
ankyrin-B and IP3 receptors are reduced in these cells in ankyrin-
B
+/2 mice (Figures S1,S2,S3). Diminished function of IP3 receptors
in calcium signaling thus may underlie some of the phenotypes
observedinankyrin-B
+/2 mice. Together,these findingssuggestthat
the 2 percent of Europeans and up to 8 percent of individualsinwest
Africathatharbor specificankyrin-B variantsmayrespondfavorably
to digitalis treatments and also have increased risk of sudden cardiac
death and diseases related to aging.
Results with ankyrin-B
+/2 mice suggest several hypotheses that
will be important to test in people. The high levels of ankyrin-B
expression in the brain and pancreatic beta cells and early
senescence in ankyrin-B
+/2 mice suggests that human populations
with age-related neurological disorders and/or type 2 diabetes
should be evaluated for ANK2 variants. Resistance of ankyrin-B
+/2
mice to ouabain-induced arrhythmia suggests that cardiac glyco-
sides could be potentially used more safely in humans with
ankyrin-B variants. Moreover, these findings suggest that in-
terference with ankyrin-B function in the heart could be
a potentially useful strategy to modify cardiac contractility.
8.6 percent of the people in our sample from Ghana are
heterozygous for the L1622I gene variant. Therefore up to 0.7
percent of this population could be homozygous for the L1622I
mutation in the absence of negative selection. While no individuals
homozygous for the L1621I variant were detected in 384
individuals, this could result from the relatively small sample size.
It will be of interest in the future to screen larger populations from
Human Ankyrin-B Gene Variants
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L1622I individuals exist, and if so whether they exhibit features of
ankyrin-B syndrome characterized so far in mice.
An obvious question is the nature of the benefit conveyed by
certain ankyrin-B variants. Resistance to malaria is an unlikely
factor, since ankyrin-B is not expressed in erythrocytes (not shown),
or in vascular endothelial cells (Figure S2), and since variants are
present in both Africans and Europeans. A simple hypothesis is that
increased cardiac contractility enhances cardiac output during
physical exertion, and thus improves survival. A corollary that can
be experimentally tested is that athletes may be more likely to have
ankyrin-B variants. Moreover, ankyrin-B variants may contribute to
sudden cardiac death among young athletes.
A striking and highly penetrant effect of ankyrin-B deficiency in
the mouse is a moderate reduction in life span accompanied by
premature senescence in multiple tissues. One hypothesis to
explain this phenotype is that disordered calcium homeostasis as
observed in ankyrin-B
+/2 cardiomyocytes [14] results in mito-
chondrial stress. Inter-relationships between calcium, mitochon-
dria, and aging have been attributed to accumulated damage from
reactive oxygen due to calcium overload of mitochondria [36]. It
will be important to evaluate effects of ankyrin-B deficiency and
loss-of-function variants on mitochondrial function.
While the ankyrin-B
+/2 mouse model has been instrumental in
demonstrating the role of ankyrin-B for normal vertebrate
physiology (Figures 2–5; [14–16,35]), the broad tissue distribution
Figure 4. Ankyrin-B
+/2 mice display premature senescence and reduced longevity. Gross phenotypes of wild-type and ankyrin-B
+/2 mice at (A)
eight weeks, (B) six months, and C) two years. While we observe no major differences in phenotypes at eight weeks, we observe a slight decrease in
size and the presence of lordokyphosis in ankyrin-B
+/2 mice at six months of age. At two years, unlike wild-type littermates, living ankyrin-B
+/2 mice
display a significant decrease in adiposity and loss of soft tissues as well as prominent lordokyphosis. D, Dorsal hair regrowth phenotypes in 12 month
C57Bl/6 wild-type and ankyrin-B
+/2 littermates. We observed no difference in regrowth in 1 or 3 month mice. E, H&E stain of dorsal skin sections from
age-matched (24 month) wild-type and ankyrin-B
+/2 littermates. Note the decrease in adipose from the subdermis of ankyrin-B
+/2 mouse skin. F,
Reduced longevity of ankyrin-B
+/2 mice compared with wild-type littermates.
doi:10.1371/journal.pone.0001051.g004
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precisely correlate animal phenotypes with specific tissue/cell
dysfunction. For example, defects in dorsal hair regrowth in
ankyrin-B
+/2 mice (Figure 4D) are indicative of impaired stem cell
regeneration. However, since ankyrin-B is also expressed in
thymus [35], an alternative hypothesis is that reduced ankyrin
function in thymus results in reduced resistance to infection or
even potential auto-immune defects associated with hair loss. A
central future focus for the field will be to use genetically-
engineered mouse and cell models to identify which specific cell
types are responsible for the global phenotypes observed in the
ankyrin-B
+/2 mouse.
In summary, this study demonstrates an unexpected prevalence
of mutations in ankyrin-B that have been linked to risk for sudden
cardiac death. We present the first evidence from a mouse model
deficient in ankyrin-B that ankyrin-B variants can be viewed as
balanced variants with increased risk of sudden death and early
aging offset by increased cardiac contractility.
SUPPORTING INFORMATION
Figure S1 InsP3R expression in Purkinje neurons is reduced in
ankyrin-B+/2 brain. Cerebellar sections from wild-type and
ankyrin-B+/2 mice were immunolabeled with affinity-purified
antibody to (A) ankyrin-B and (B) InsP3R (pan). Wild-type and
ankyrin-B +/2 sections were prepared, stained, and imaged using
identical protocols. Scale bar equals 50 microns.
Found at: doi:10.1371/journal.pone.0001051.s001 (5.10 MB TIF)
Figure S2 Ankyrin-B expression at the apical membrane of
airway epithelial cells is significantly reduced in ankyrin-B+/2
lung. Lung sections from wild-type and ankyrin-B+/2 mice were
immunolabeled with affinity-purified antibodies for beta-tubulin
and ankyrin-B. No staining was observed using non-immune
serum. Scale bars from top to bottom equal 100, 30, 100, and
25 microns. Wild-type and ankyrin-B+/2 tissue sections were
prepared and imaged identically. Abbreviations: Bronchus (Br),
apical (ap), smooth muscle (sm), alveoli (al), artery (A).
Found at: doi:10.1371/journal.pone.0001051.s002 (3.19 MB TIF)
Figure S3 InsP3R expression is exclusively reduced in ankyrin-
B+/2 lung where co-expressed with ankyrin-B. InsP3R localiza-
tion with co-labeling of beta-tubulin (columnar epithelial cells) in
wild-type and ankyrin-B+/2 lung sections. InsP3R (pan InsP3R)
is highly expressed at the apical membrane of epithelial cells and in
smooth muscle. No staining was observed using pre-immune
serum. Bottom, reduction of ankyrin-B in ankyrin-B +/2 lung is
associated with InsP3R reduction at the apical membrane of
epithelial cells, while there is no reduction in smooth muscle
InsP3R. Scale bars from top to bottom equal 100, 20, 100, and
15 microns. Wild-type and ankyrin-B +/2 tissue sections were
Figure 5. Ankyrin-B-haploinsufficiency in multiple cell types. A, Relative 220 kD ankyrin-B expression across mouse tissues. Right panel illustrates
expression of 220 kD ankyrin-B in ankyrin-B
+/2 mouse tissues compared with wild-type littermate tissue (n.3, p,0.05). B, Quantitative immunoblot
of 220 kD ankyrin-B expression in wild-type and ankyrin-B
+/2 mouse pancreas using ankyrin-B Ig. Protein levels were quantified by 125-labeled
Protein A (n.3). C–D, Immunolocalization of glucagon (left) and ankyrin-B (right) in the Islet of wild-type mouse pancreas. Note that we observe no
immunoreactivity of ankyrin-B in the exocrine pancreas. E, Immunolocalization of somatostatin and ankyrin-B in wild-type islets. We observe no co-
expression of ankyrin-B and somatostatin in delta cells. F, Immunolocalization of glucagon and ankyrin-B in wild-type mouse islets. We observe no co-
localization of glucagon and ankyrin-B in alpha cells. G, Immunolocalization of glucagon and ankyrin-B in Islets of ankyrin-B
+/2 mice. Note the
significant decrease in ankyrin-B levels.
doi:10.1371/journal.pone.0001051.g005
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apical (ap), smooth muscle (sm), alveoli (al), artery (A).
Found at: doi:10.1371/journal.pone.0001051.s003 (3.17 MB TIF)
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